MYL : NASDAQ : Health Care
$30.56 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 6243400.0
08/17/17 - 4:00 PM ET

Financial Analysis

MYLAN NV's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.74 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 24.23% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)2962.22560.7
EBITDA ($mil)905.8787.7
EBIT ($mil)497.6484.3
Net Income ($mil)297.0168.4

Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)876.36518.0
Total Assets ($mil)35506.228836.3
Total Debt ($mil)14989.913483.4
Equity ($mil)12832.910329.9

Profitability Q2 FY17 Q2 FY16
Gross Profit Margin56.2358.53
EBITDA Margin30.5730.76
Operating Margin16.818.91
Sales Turnover0.340.34
Return on Assets1.862.79
Return on Equity5.157.79
Debt Q2 FY17 Q2 FY16
Current Ratio1.353.23
Interest Expense128.054.4
Interest Coverage3.898.9

Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)536.12508.42
Div / share0.00.0
Book value / share23.9420.32
Institutional Own % n/a n/a
Avg Daily Volume5853664.05936264.0


HOLD. The current P/E ratio indicates a discount compared to an average of 28.08 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 24.31. For additional comparison, its price-to-book ratio of 1.35 indicates a significant discount versus the S&P 500 average of 3.03 and a significant discount versus the industry average of 16.44. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MYL 26.47 Peers 28.08   MYL 6.80 Peers 25.61

Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.

MYL is trading at a valuation on par with its peers.


Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MYL is trading at a significant discount to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
MYL 6.18 Peers 14.98   MYL 0.07 Peers 0.61

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MYL is trading at a significant discount to its peers.


Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MYL trades at a significant discount to its peers.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MYL 1.35 Peers 16.44   MYL -22.30 Peers 25.27

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MYL is trading at a significant discount to its peers.


Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MYL is expected to significantly trail its peers on the basis of its earnings growth rate.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MYL 1.44 Peers 6.45   MYL 20.81 Peers 8.29

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MYL is trading at a significant discount to its industry on this measurement.


Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

MYL has a sales growth rate that significantly exceeds its peers.



Latest Stock Upgrades/Downgrades